Zai Lab (ZLAB) announced the appointment of Dr. Peter Huang as its Chief Scientific Officer, CSO, effective immediately. Dr. Huang will report to Josh Smiley, Chief Operating Officer of Zai Lab, and will be a key member of the Company’s executive committee. He will lead and oversee the Company’s discovery efforts and translational medicine. Dr. Huang joins Zai Lab from Zentalis Pharmaceuticals (ZNTL) where he held various roles of increasing responsibility from March 2015 to October 2022. Most recently, Dr. Huang served as Senior Vice President of Discovery Research for Zentalis from October 2020
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ZLAB:
- Zai Lab to Present New Oncology Research at 2022 Society for Immunotherapy of Cancer Annual Meeting
- Zai Lab Announces the Appointment of Dr. Peter Huang as Chief Scientific Officer
- Zai Lab Announces Participation in November Investor Conferences
- Zai Lab to Announce Third Quarter 2022 Financial Results on November 9, 2022
- Zai Lab Launches its first Trust Report